The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) focuses on improving the lives of people with eosinophilic gastrointestinal disorders (EGIDs).

These disorders include eosinophilic oesophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC). They involve chronic inflammation in the gastrointestinal tract due to an excessive build-up of a type of white blood cell called eosinophils.

Their Approach

CEGIR brings together scientists, healthcare providers, patients, and professional organisations to advance research, clinical expertise, and education in this field.

By combining knowledge from different areas like gastroenterology, allergy, immunology, and pathology, CEGIR takes a collaborative approach to understanding and addressing these conditions in children and adults.

Our regular meetings provide a platform for exchanging ideas and exploring innovative approaches to research and clinical practice. By staying connected and informed, we aim to remain at the forefront of knowledge and deliver the highest quality care and research.

The organisation is funded by the National Institutes of Health (NIH) and is part of the Rare Diseases Clinical Research Network (RDCRN).

Diversity and Inclusion in Our Research

CEGIR values diversity and inclusivity, actively promoting these principles in its membership, research studies, and educational initiatives.

In response to longstanding, systemic racial, cultural and gender injustices that have affected healthcare delivery, CEGIR developed a committee to focus on diversity and inclusion in our research and education activities. These efforts will improve the care for underrepresented populations with EGIDs.

The Consortium

CEGIR consists of four primary cores: Clinical Research Projects 1 and 2, Pilot/Demonstration Clinical Research Programme, and Training Programme.

An Administrative Core coordinates these efforts.

Clinical Research Project 1 (OMEGA Trial)

Aims to correlate clinical outcome measures (COMs) and patient-reported outcomes (PROs) with histological disease activity. It aims to identify disease-specific molecular diagnostic criteria, gain insights into disease pathogenesis, and explore the molecular basis of different clinical phenotypes.

Clinical Research Project 2 (SOFEED Trial)

Evaluates the efficacy of restricted diets and develops personalised medicine approaches aiming to provide effective and tailored care for individuals living with EoE, improving their quality of life.

The Pilot/Demonstration Clinical Research Programme

Supports innovative projects, while the Training Programme fosters new investigators in the field who will improve care for patients with eosinophilic gastrointestinal diseases.

Patient Advocacy Groups 

Play a crucial role in raising awareness and providing resources and support for eosinophilic gastrointestinal diseases.

EOS Network is proud to be an international patient advocate partner with CEGIR serving as a community for patients and a professional hub for healthcare professionals.

Our goal within CEGIR is to communicate the latest developments, gather patient perspectives, and offer support for research and clinical efforts.

As a partner of CEGIR, we also translate complex updates into language that patients can easily understand and share knowledge with healthcare professionals worldwide to improve global expertise.

Please Donate

See the latest CEGIR research on the milk elimination diet

Latest CEGIR Newsletter (2020)

Join one of the CEGIR's studies RESEARCH STUDIES